Table 2.
Demographic and clinical information of study subjects
| Partners (n=500) | Northwestern (n=390) | Vanderbilt (n=376) | ||||
| RA | Non-RA | RA | Non-RA | RA | Non-RA | |
| Total | 96 (19.2%) | 404 (80.8%) | 102 (26.2%) | 288 (73.8%) | 185 (49.2%) | 191 (50.8%) |
| Age (years) | 60.7±15.9 | 56.0±18.6 | 54.3±14.8 | 58.9±16.8 | 52.9±13.1 | 56.2±16.5 |
| Women | 74 (77.1%) | 303 (75.0%) | 83 (81.4%) | 209 (72.6%) | 148 (80.0%) | 141 (73.8%) |
| Ethnicity | ||||||
| Caucasian | 64 (66.7%) | 286 (70.8%) | 40 (39.2%) | 120 (41.7%) | 143 (77.3%) | 155 (81.2%) |
| African American | 3 (3.1%) | 46 (11.4%) | 18 (17.6%) | 46 (16.0%) | 14 (7.6%) | 26 (13.6%) |
| Hispanic | 2 (2.1%) | 29 (7.2%) | 6 (5.9%) | 18 (6.3%) | 1 (0.5%) | 1 (0.5%) |
| Other | 6 (6.3%) | 7 (1.7%) | 13 (12.7%) | 44 (15.3%) | 3 (1.6%) | 2 (1.0%) |
| Unknown | 21 (21.9%) | 36 (8.9%) | 25 (24.5%) | 60 (20.8%) | 24 (13.0%) | 7 (3.7%) |
| Drugs | ||||||
| Anti-TNF use | 50 (52.1%) | 50 (12.4%) | 67 (65.7%) | 37 (12.8%) | 88 (47.6%) | 26 (13.6%) |
| Methotrexate | 77 (80.2%) | 105 (26.0%) | 70 (68.6%) | 61 (21.2%) | 133 (71.9%) | 63 (33.0%) |
| Codes | ||||||
| RA | 93 (96.9%) | 329 (81.4%) | 102 (100.0%) | 283 (98.3%) | 185 (100.0%) | 191 (100.0%) |
| SLE | 2 (2.1%) | 37 (9.2%) | 3 (2.9%) | 22 (7.6%) | 14 (7.6%) | 32 (16.8%) |
| JRA | 7 (7.3%) | 28 (6.9%) | 1 (1.0%) | 18 (6.3%) | 6 (3.2%) | 8 (4.2%) |
| PsA | 2 (2.1%) | 21 (5.2%) | 0 (0.0%) | 12 (4.2%) | 6 (3.2%) | 14 (7.3%) |
| EHR follow-up* | 9.38±6.77 | 10.14±6.85 | 6.30±4.69 | 6.05±4.85 | 9.97±4.06 | 9.06±4.32 |
*
Mean±SD in years, calculated as first ICD-9 code to last.
EHR, electronic health record; ICD-9, International Classification of Diseases, version 9 CM; JRA, juvenile rheumatoid arthritis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; TNF, tumour necrosis factor.